scholarly journals CV4 Patients with Hypercholesterolaemia or MIXED Dyslipidaemia and High or VERY High Cardiovascular Risk According to ESC/EAS Guidelines – a Population-Based CROSS–Sectional Study from the Netherlands

2020 ◽  
Vol 23 ◽  
pp. S401
Author(s):  
E. Heintjes ◽  
J. Kuiper ◽  
A. Anastassopoulou ◽  
F. Penning-van Beest ◽  
A. Bilitou ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
The Netherlands ◽  
Population Based ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
High Cardiovascular Risk ◽  
Cross Sectional ◽  
Very High

scholarly journals Prevalence of abdominal obesity and its association with cardiovascular risk among the adult population in Burkina Faso: findings from a nationwide cross-sectional study

BMJ Open ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. e049496
Author(s):  
Kadari Cisse ◽  
Sékou Samadoulougou ◽  
Mady Ouedraogo ◽  
Seni Kouanda ◽  
Fati Kirakoya-Samadoulougou
Keyword(s):  
Cardiovascular Risk ◽  
Burkina Faso ◽  
Weight Management ◽  
Abdominal Obesity ◽  
Urban Areas ◽  
Adult Population ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Very High

ObjectiveThe objective of this study is to determine the prevalence of abdominal obesity, its predictors and its association with cardiovascular risk among adults in Burkina Faso.DesignWe performed a secondary analysis of data from a national cross-sectional study, using WHO STEPwise approach.SettingThe study was conducted in Burkina Faso, in all the 13 regions of the country.ParticipantsOur study involved 4308 adults of both sexes, aged between 25 and 64 years.Primary and secondary outcomesOur primary outcome was abdominal obesity, which was defined using a cut-off point of waist circumference (WC) of ≥94 cm for men and ≥80 cm for women. The secondary outcome was very high WC (≥102 cm for men and ≥88 cm for women) (for whom weight management is required).ResultsThe mean age of participants was 38.5±11.1 years. The age-standardised prevalence of abdominal obesity was 22.5% (95% CI 21.3% to 23.7%). This prevalence was 35.9% (95% CI 33.9% to 37.9%) among women and 5.2% (95% CI 4.3% to 6.2%) among men. In urban areas, the age-standardised prevalence of abdominal obesity was 42.8% (95% CI 39.9% to 45.7%) and 17.0% (95% CI 15.7% to 18.2%) in rural areas. The age-standardised prevalence of very high WC was 10.2% (95% CI 9.3% to 11.1%). The main predictors of abdominal obesity were being female, increased age, married status, high level of education and living in urban areas. Abdominal obesity was also significantly associated with high blood pressure (adjusted prevalence ratio (aPR): 1.30; 95% CI 1.14 to 1.47) and hypercholesterolaemia (aPR: 1.52; 95% CI 1.18 to 1.94). According to the combination matrix between body mass index and WC, 14.6% of the adult population in Burkina Faso had an increased cardiometabolic risk.ConclusionOur study showed a high prevalence of abdominal obesity and a high proportion of adults who require weight management strategies to prevent cardiometabolic complications. Strategies to reduce the burden of abdominal obesity and very high WC should be considered by Burkina Faso’s policy-makers.

scholarly journals Change in calculated cardiovascular risk due to guideline revision: A cross-sectional study in the Netherlands

2015 ◽  
Vol 21 (4) ◽  
pp. 217-223 ◽  
Author(s):  
Clare H Luymes ◽  
Wouter de Ruijter ◽  
Rosalinde KE Poortvliet ◽  
Hein Putter ◽  
Huug J van Duijn ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
The Netherlands ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional

Obesity, dynapenia and high cardiovascular risk co-exist in post-liver transplant setting: results of a cross-sectional study

2019 ◽  
Vol 43 (2) ◽  
pp. 140-147 ◽  
Author(s):  
Bruna Cherubini Alves ◽  
Juliana Paula Bruch-Bertani ◽  
Clara Belle Manfroi Galinatti ◽  
Claudia Czarnobay Garbin ◽  
Mário Reis Álvares-da-Silva ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Liver Transplant ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
High Cardiovascular Risk ◽  
Cross Sectional

Atorvastatin-Therapie in der Praxis – LDL-Werte bei Patienten mit sehr hohem kardiovaskulären Risiko

2017 ◽  
Vol 142 (16) ◽  
pp. 1249-1252
Author(s):  
Ulrich Laufs ◽  
Christina Jannowitz ◽  
David Pittrow
Keyword(s):  
Cardiovascular Risk ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Subjective Assessment ◽  
Cross Sectional Study ◽  
High Cardiovascular Risk ◽  
Cross Sectional ◽  
Current Guidelines ◽  
Very High

AbstractCurrent information on the utilisation of atorvastatin under clinical practice conditions is limited. The cross sectional study DISCOVER documented in the period from June until December 2014 dose and effects on lipids in ambulatory patients at very high cardiovascular risk, who were treated with atorvastatin monotherapy (original drug or generics). Of 2625 patients (mean age 66.1 ± 10.8 years, 62.1 % males), 47.0 % had coronary heart disease (CHD), 25.1 % type 2 diabetes mellitus (DM), and 27.9 % CHD plus concomitant DM. Mean treatment duration on atorvastatin was 92.6 ± 109.6 weeks, mean atorvastatin dose at time of documentation was 27.9 ± 15.8 mg/d. Low-density lipoprotein cholesterol (LDL-C) < 70 mg/dL was achieved by 10.5 % of the total cohort (7.5 % in DM, 9.3 % in CHD, and 15.2 % in CHD+DM). In contrast, according to physicians’ subjective assessment, 62.7 % of patients reached their individual LDL-C target (with small differences between groups). In conclusion, the LDL-C target level < 70 mg/dL as recommended by current guidelines is achieved only in a minority of atorvastatin treated patients at very high cardiovascular risk.

Sign in / Sign up

Export Citation Format

Share Document